WO2013190867A1 - 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット - Google Patents
膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット Download PDFInfo
- Publication number
- WO2013190867A1 WO2013190867A1 PCT/JP2013/055828 JP2013055828W WO2013190867A1 WO 2013190867 A1 WO2013190867 A1 WO 2013190867A1 JP 2013055828 W JP2013055828 W JP 2013055828W WO 2013190867 A1 WO2013190867 A1 WO 2013190867A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pancreatic juice
- protease inhibitor
- room temperature
- sample
- juice component
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/28—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen, oxygen and sulfur
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Definitions
- the present invention includes a method for preparing a preservation sample capable of stably storing S100P contained in pancreatic juice at room temperature until it is used for examination, and a pancreatic juice component suitable for the method.
- the present invention relates to a kit for storing a biological sample at room temperature.
- Body fluid is an important biological sample for knowing the state of an organ.
- pancreatic juice is an important biological sample that contributes to early detection of pancreatic cancer, which is difficult to detect at an early stage and has a very poor prognosis. Cytodiagnosis, bicarbonate measurement, bacterial testing, and testing for markers such as proteins and nucleic acids Etc. are used. In recent years, research for analyzing proteins in pancreatic juice, for example, searching for new markers for pancreatic-related diseases such as pancreatic cancer has been actively conducted.
- S100P which is a member of the S100 protein family and is a receptor for advanced glycation end product (receptor for advanced glycation endproducts: RAGE), has been confirmed to be expressed in a large number of pancreatic cancers, and is associated with the proliferation and invasion of pancreatic cancer It is reported to be involved.
- Non-Patent Document 1 reports that S100P is useful as an early carcinogenic marker for pancreas, and that S100P concentration analysis in pancreatic juice is useful for distinguishing between tumor and chronic pancreatitis.
- Non-Patent Document 2 reports that S100P expression was not observed in normal pancreatic duct epithelium, but S100P expression was observed in all specimens in intraductal papillary mucinous tumor cells. That is, S100P is useful as a marker for pancreatic cancer, and is expected to contribute to early detection of pancreatic cancer, diagnosis of progression, etc. by measuring the amount of S100P in pancreatic juice.
- pancreatic juice is a digestive juice, it contains various digestive enzymes. These digestive enzymes exist in an inactive state in the pancreas, but are known to be activated after excretion into the duodenum.
- the digestive enzyme in pancreatic juice undergoes a cascade reaction of degradation by small intestinal enterokinase secreted from duodenal epithelial cells. It is known that trypsinogen contained in pancreatic juice is activated by small intestinal enterokinase to become trypsin, and this trypsin is triggered to activate various digestive enzymes (proteases) such as chymotrypsinogen and proesterase. .
- pancreatic juice and duodenal juice collected from living organisms are stored frozen until they are subjected to S100P examination, so that the degradation / denaturation of S100P during the storage period is suppressed to some extent. It seems possible. However, when the S100P test is performed as a clinical test, considering that it is difficult to say that all medical institutions and test institutions have adequate specimen storage facilities, pancreatic juice and duodenal juice collected from living organisms are considered. It is desirable that it can be stored at room temperature as much as possible until it is used for inspection.
- pancreatic juice or duodenal juice is stored at room temperature
- the activity of proteases derived from pancreatic juice or duodenal juice can be maintained even at room temperature so that S100P contained in these specimens can be stably stored. Must be sufficiently inhibited.
- a method for storing a solution containing a biological component at room temperature for example, in performing immunoassay such as enzyme immunoassay and radioimmunoassay in the field of clinical examination, a sample containing an antigen to be measured, As a method for preventing the inactivation of the antigen in the sample and stably storing it in a solution state, there is a method of adding casein or whey protein to the sample (for example, see Patent Document 1). Further, as a method for stably storing body fluid at room temperature, there is also a method in which a target body fluid is immersed in a test tool in which a protease inhibitor is held in a porous material and then dried (for example, Patent Documents). 2).
- Patent Document 1 Although the method described in Patent Document 1 is effective for a sample with very few contaminants such as protease such as a standard solution used for immunoassay, it is originally a large amount such as pancreatic juice and duodenal juice. The effect cannot be expected much for a sample containing protease.
- Patent Document 2 preserves a specimen in a dry state, and thus is effective to some extent for substances that are not easily denatured by a drying process, such as peptides, but proteins such as S100P May be affected by the three-dimensional structure by the drying treatment and may be denatured.
- Patent Document 2 describes many protease inhibitors that can be retained in a porous material, a protease inhibitor optimized to suppress the degradation of S100P in pancreatic juice and duodenal juice The combination of is not disclosed. For this reason, even if pancreatic juice etc. are preserve
- the present invention relates to a method for preparing a pancreatic juice component-containing sample capable of stably storing S100P at room temperature among proteins in a biological sample containing pancreatic juice components such as pancreatic juice and duodenal juice, and the method. It is an object of the present invention to provide a kit for storing a biological sample containing a suitable pancreatic juice component at room temperature.
- the present inventors combined a biological sample containing a pancreatic juice component with a protease inhibitor having a sulfonyl fluoride group and a specific type of trypsin-like serine protease inhibitor.
- a biological sample containing a pancreatic juice component with a protease inhibitor having a sulfonyl fluoride group and a specific type of trypsin-like serine protease inhibitor.
- the method for preparing a pancreatic fluid component-containing sample and the kit for preserving a pancreatic fluid component-containing sample of the present invention have the following configurations (1) to (10).
- the method for preparing a pancreatic fluid component-containing sample according to (1) further comprising a step of storing the pancreatic fluid component-containing sample at room temperature after the step of preparing the pancreatic fluid component-containing sample.
- the protease inhibitor having a sulfonyl fluoride group is PMSF, AEBSF, p-APMSF, 4- (fluorosulfonyl) benzoic acid, 3- (fluorosulfonyl) benzoic acid, 2-aminobenzenesulfonyl fluoride, 3 -Pancreatic fluid of (1) above, selected from the group consisting of aminobenzenesulfonyl fluoride, 4-aminobenzenesulfonyl fluoride, 2-nitrobenzenesulfonyl fluoride, 3-nitrobenzenesulfonyl fluoride, and 4-nitrobenzenesulfonyl fluoride Preparation method of component-containing sample.
- a kit for preserving a biological sample containing a pancreatic juice component at room temperature comprising at least one protease inhibitor having a sulfonyl fluoride group; and at least one trypsin-like serine protease inhibitor that is an amino acid chloromethyl ketone. .
- the kit for room temperature storage according to any one of the above (8) to (10).
- the method for preparing a pancreatic juice component-containing sample of the present invention enables a biological sample containing a pancreatic juice component to be stably stored at room temperature while sufficiently suppressing the degradation and denaturation of S100P contained in the biological sample.
- Simple storage samples can be prepared. That is, it is possible to provide a high-quality sample by more stably storing proteins in pancreatic juice that are very easily decomposed, and it can be expected to contribute to acceleration of research on pancreatic cancer.
- the method for preparing a pancreatic juice component-containing sample of the present invention is expected to be widely applied to clinical examinations.
- kits for room temperature preservation of a biological sample containing the pancreatic juice component of the present invention a biological sample for S100P examination that can be stored at room temperature can be more easily prepared from pancreatic juice or duodenal fluid collected from the living body. be able to.
- Pancreatic juice is a bodily fluid drained from the pancreatic duct.
- a biological sample containing a pancreatic juice component means a sample containing a body fluid containing a component derived from pancreatic juice.
- the body fluid containing the pancreatic juice-derived component include pancreatic fluid collected directly from the pancreas from a catheter, fluid collected from the duodenum (duodenal fluid), and the like.
- duodenal fluid also includes bile discharged from the nipple, fluid originally present in the duodenum, blood, and the like.
- pancreatic juice and duodenal juice can be collected by a conventional method.
- the method for preparing a pancreatic juice component-containing sample of the present invention includes a biological sample containing a pancreatic juice component even at room temperature.
- this is a method of preparing so that the decomposition and modification of S100P can be suppressed and can be stably stored. That is, in the preparation method of the present invention, at least one protease inhibitor having a sulfonyl fluoride group and at least one trypsin-like serine protease inhibitor that is an amino acid chloromethyl ketone are added to a biological sample containing a pancreatic juice component. And a step of preparing a pancreatic juice component-containing sample, and if necessary, further comprising a step of storing the sample at room temperature until it is used for detection of S100P.
- a biological sample containing pancreatic juice components such as pancreatic juice and duodenal juice contains a large amount of protease in addition to the protein to be examined (S100P in the preparation method of the present invention)
- the biological sample Is stored at room temperature
- the target protein is degraded and denatured by the effect of protease.
- the biological sample is stored after being stored at room temperature, even if the biological sample contains the protein immediately after collection from the living body, the protein is not detected in the inspection, and the inspection accuracy is improved. There is a problem of lowering.
- the activity of the protease derived from the biological sample can be effectively suppressed even in a solution state at room temperature. Stability can be dramatically improved. That is, the pancreatic juice component-containing sample obtained by the preparation method of the present invention has an unprecedented high quality even after storage at room temperature and is suitable for S100P inspection (examination for detecting S100P) that requires high accuracy. Is preferred.
- a trypsin-like serine protease inhibitor that is at least one protease inhibitor having a sulfonyl fluoride group and an amino acid chloromethyl ketone is added to a biological sample containing a pancreatic juice component.
- specific trypsin-like serine protease inhibitor is added to prepare a pancreatic juice component-containing sample.
- proteases in pancreatic juice and duodenal juice by amino acid chloromethyl ketones having an inhibitory activity against trypsin-like serine protease such as TLCK (Na-tosyl-L-lysine chloromethyl ketone)
- TLCK Na-tosyl-L-lysine chloromethyl ketone
- a protease inhibitor having a sulfonyl fluoride group and leupeptin can be obtained by using a protease inhibitor having a sulfonyl fluoride group in combination with a trypsin-like serine protease inhibitor that is an amino acid chloromethyl ketone such as TLCK.
- a trypsin-like serine protease inhibitor that is an amino acid chloromethyl ketone such as TLCK.
- the protease inhibitor having a sulfonyl fluoride group used in the preparation method of the present invention is not particularly limited as long as it is a compound having a sulfonyl fluoride group and having protease inhibitory activity.
- a compound having a structure in which a sulfonyl fluoride group is bonded directly or via a hydrocarbon group having 1 to 6 carbon atoms is preferable.
- PMSF phenylmethylsulfonyl fluoride
- AEBSF 2- (2-aminoethyl) -Benzenesulfonyl fluoride
- p-APMSF p-amidinophenylmethanesulfonyl fluoride hydrochloride
- 4- (fluorosulfonyl) benzoic acid CAS number: 455-26-5
- 3- (fluorosulfonyl) benzoic acid Acid CAS number: 454-95-5
- 2-aminobenzenesulfonate Rufluoride CAS number: 392-86-9
- 3-aminobenzenesulfonyl fluoride CAS number: 368-50-3
- 4-aminobenzenesulfonyl fluoride CAS number: 98-62-4
- 2- Nitrobenzenesulfonyl fluoride CAS number: 433-98-7
- 3-nitrobenzenesulfonyl fluoride CAS number:
- protease inhibitor having a sulfonyl fluoride group used in the preparation method of the present invention may be used, or two or more types may be used in combination.
- at least one compound selected from the group consisting of PMSF, AEBSF, and p-APMSF is preferably used, and two or more compounds selected from the group consisting of PMSF, AEBSF, and p-APMSF are used in combination. More preferably, all three types may be used.
- pancreatic juice contains various proteases having different activities, it can be expected that protease activity in a biological sample is more reliably suppressed by using a mixture of a plurality of protease inhibitors. Furthermore, the protease activity can be expected to be suppressed by combining at a lower concentration than when used alone.
- the amount of the protease inhibitor having a sulfonyl fluoride group added to the biological sample containing the pancreatic juice component is particularly limited as long as the protease inhibitory effect by the protease inhibitor and the room temperature stability improving effect of S100P are exhibited. However, it can be appropriately adjusted in consideration of the type of biological sample containing pancreatic juice components, the type of protease inhibitor used, and the like. For example, when only PMSF is added as a protease inhibitor having a sulfonyl fluoride group to a biological sample containing a pancreatic juice component, the final concentration should be 1 mM or more, preferably 5 mM or more, more preferably 10 mM or more. Can do.
- AEBSF is added to a biological sample containing pancreatic juice components so that the final concentration is 4 mM or more, preferably 10 mM or more, more preferably 20 mM or more. can do.
- AEBSF is added to a biological sample containing pancreatic juice components so that the final concentration is 2 mM or more, preferably 5 mM or more, more preferably 10 mM or more. can do.
- the trypsin-like serine protease inhibitor used in the preparation method of the present invention is not particularly limited as long as it is an amino acid chloromethyl ketone and is a compound having an inhibitory activity against trypsin-like serine protease typified by trypsin. Absent. In the present invention, it is particularly preferable to use TLCK.
- the amount of the specific trypsin-like serine protease inhibitor added to the biological sample containing the pancreatic juice component is particularly limited as long as the protease inhibitory effect by the protease inhibitor and the room temperature stability improving effect of S100P are exhibited. However, it can be appropriately adjusted in consideration of the type of biological sample containing the pancreatic juice component, the type of protease inhibitor used, and the like. For example, when only TLCK is added as a specific trypsin-like serine protease inhibitor to a biological sample containing pancreatic juice components, the final concentration is 0.1 mM or more, preferably 1 mM or more, more preferably 5 mM or more, and even more preferably 10 mM or more. Can be added.
- the protease inhibitor having a sulfonyl fluoride group and the specific trypsin-like serine protease inhibitor added to a biological sample containing a pancreatic juice component are in a solid form such as powder or granule. It may be a protease inhibitor solution dissolved in an appropriate buffer or the like.
- the protease inhibitor having a sulfonyl fluoride group and the specific trypsin-like serine protease inhibitor may be added simultaneously to a biological sample containing pancreatic juice components, and after adding one of them first, It may be added.
- the protease inhibitor having a sulfonyl fluoride group and the specific trypsin-like serine protease inhibitor are added simultaneously.
- protease inhibitor having a sulfonyl fluoride group and the specific trypsin-like serine protease inhibitor may be added to a biological sample containing pancreatic juice components, and other protease inhibitors may be added. Further, it may be added.
- Other protease inhibitors are not particularly limited as long as they do not impair the room temperature stability improving effect of S100P of the present invention.
- pancreatitis therapeutic agents such as gabexate mesylate (FOY), camostat mesilate (Foipan), nafamostat mesylate (Futan), urinastatin and the like can also be used.
- the biological sample containing the pancreatic juice component used in the preparation method of the present invention may be a sample containing a bodily fluid containing a pancreatic juice-derived component, and consists only of a bodily fluid containing a pancreatic juice-derived component. It may be a solution obtained by diluting the body fluid with an appropriate buffer or the like, or may be one obtained by adding various additives to the body fluid or a diluted solution thereof. Examples of the additive include a surfactant, a nucleolytic enzyme inhibitor, a pH adjuster, and a pH indicator.
- the biological sample containing the pancreatic juice component used in the preparation method of the present invention is preferably a sample containing pancreatic juice or duodenal juice. Specific examples include pancreatic juice, duodenal fluid, pancreatic juice, or a diluted solution of duodenal fluid, or a solution obtained by adding the aforementioned various additives to these.
- a protease sample having a sulfonyl fluoride group and a trypsin-like serine protease inhibitor which is an amino acid chloromethyl ketone is added to a biological sample containing a pancreatic juice component that has been collected from a living body and stored.
- the interval from the time when the body fluid containing the pancreatic juice component is collected from the living body to the time when the protease inhibitor is added is shorter, and the pancreatic juice or the duodenal juice immediately after collection from the living body is preferably used. It is particularly preferable to add a protease inhibitor.
- Biological samples containing pancreatic juice have a very strong action of the contained protease, and protein degradation may proceed immediately after collection, so the time lag until the collected biological sample and the protease inhibitor are mixed is shortened This is because it is preferable.
- a protease inhibitor and amino acid having a sulfonyl fluoride group in advance in a reservoir (a container-like member for storing collected body fluid) provided in a collection tool for collecting pancreatic juice or duodenal fluid from a living body
- a trypsin-like serine protease inhibitor which is a chloromethyl ketone
- pancreatic juice or duodenal juice collected from a living body is immediately mixed with the protease inhibitor in a collection container.
- a protease inhibitor having a sulfonyl fluoride group and an amino acid chloromethyl ketone in advance in the storage container A trypsin-like serine protease inhibitor, which is a kind, is filled.
- pancreatic juice component-containing sample prepared by the preparation method of the present invention can sufficiently exhibit its effect by being stored at room temperature, but may be cryopreserved or refrigerated.
- the S100P test performed on the pancreatic juice component-containing sample prepared by the preparation method of the present invention is not particularly limited as long as the test is performed for the purpose of detecting or quantifying S100P.
- various protein analyzes using ELISA, immunochromatography, two-dimensional electrophoresis, Western blot, mass spectrometry, etc. various nucleic acid analyzes using PCR, RT-PCR, hybridization using probes, etc.
- S100P can be detected by cell analysis such as counting or cytodiagnosis.
- the preparation method of the present invention is expected to improve the room temperature stability of pancreatic juice-derived components other than S100P.
- the pancreatic juice component-containing sample prepared by the preparation method of the present invention can be used as a measurement sample for various examinations of components other than S100P in the pancreatic fluid-containing component sample.
- the substance to be examined is not particularly limited as long as it is a biological component expected to be contained in pancreatic juice or duodenal juice, and may be a protein or a nucleic acid such as DNA or RNA. It may be a cell.
- pancreatic juice component-containing sample was subjected to various protein analyzes using ELISA, immunochromatography, two-dimensional electrophoresis, Western blot, mass spectrometry, etc., PCR, RT-PCR, hybridization using probes, etc. It can be used for various nucleic acid analysis, cell analysis such as cell count and cytodiagnosis.
- the biological sample storage kit containing the pancreatic juice component of the present invention includes at least one protease inhibitor having a sulfonyl fluoride group and the amino acid chloromethyl. It has at least one trypsin-like serine protease inhibitor which is a ketone. A protease inhibitor having a sulfonyl fluoride group and a specific trypsin-like serine protease inhibitor provided in the storage kit are added to a biological sample containing a pancreatic juice component to be used for detection of S100P. In the meantime, a sample containing pancreatic juice components that can be stored at room temperature can be more easily prepared.
- the protease inhibitor having a sulfonyl fluoride group contained in the preservation kit of the present invention may be only one kind or a combination of two or more kinds. In the present invention, it is preferable to use one or more compounds selected from the group consisting of PMSF, AEBSF, and p-APMSF, and it is more preferable to use two or more compounds selected from these compound groups. . Similarly, only one type of trypsin-like serine protease inhibitor contained in the preservation kit of the present invention may be used, or two or more types may be combined. In the present invention, TLCK is preferably used as a trypsin-like serine protease inhibitor.
- the various protease inhibitors contained in the preservation kit of the present invention may be lyophilized powder, or may be tablets or granules obtained by molding the lyophilized powder together with an appropriate excipient or the like.
- a protease inhibitor solution dissolved in an appropriate buffer may be used.
- the storage kit of the present invention may further contain a buffer for diluting the collected body fluid, other protease inhibitors, surfactants, pH adjusters, pH indicators and the like.
- Various additives such as a surfactant, a pH adjuster, and a pH indicator may be previously dissolved in a dilution buffer.
- the preservation kit of the present invention comprises a prepared pancreatic juice component-containing sample (a biological sample containing a pancreatic juice component is added with various protease inhibitors contained in the preservation kit of the present invention, and other components as necessary.
- a cap that can be bonded to the opening of the container that allows a certain amount to be dropped from the container filled with the pancreatic juice component-containing sample.
- the preservation kit of the present invention may include a preservation container having a reservoir for storing a body fluid such as pancreatic juice or duodenal juice collected from a living body.
- a body fluid such as pancreatic juice or duodenal juice collected from a living body.
- the protease inhibitor of the present invention is previously contained in the reservoir. If the storage container is graduated, the amount of biological sample added to the storage container (if the storage container is pre-filled with a protease inhibitor, the biological sample and protease The total amount of inhibitors) can be visually confirmed and thus the final concentration of protease inhibitors can be understood at a glance.
- a biological sample containing a pancreatic juice component is generally collected transendoscopically. Therefore, as a component of the preservation kit of the present invention, a collection tool for collecting a biological sample containing a pancreatic juice component endoscopically may be included.
- the collecting tool include a combination of a syringe and a catheter that can be inserted into an endoscope apparatus, and a probe that includes an absorber that can be inserted into an endoscope apparatus at the tip.
- the catheter that can be inserted into the endoscope apparatus include a sample collection cube described in Japanese Patent Application Laid-Open No. 2011-5009.
- These collection tools preferably have a storage part into which the protease inhibitor is dispensed in advance. Moreover, when the said storage part is removable, it can be used also as a storage container.
- protease inhibitors used were aprotinin (Roche), leupeptin (Roche), PMSF (Roche), AEBSF (Roche), p-APMSF (SIGMA), camostat mesylate (Foipan; Wako Pure Chemical Industries, Ltd.), gabexate mesylate (FOY; manufactured by Wako Pure Chemical Industries, Ltd.), TLCK (manufactured by SIGMA), and TPCK (manufactured by SIGMA).
- TPCK is an amino acid chloromethyl ketone that has inhibitory activity against chymotrypsin but does not show inhibitory activity against trypsin.
- the measurement results of the fluorescence amount of each pancreatin solution are shown in FIG.
- the amount of fluorescence on the vertical axis represents the amount of casein decomposed, and the value was estimated as the protease activity value.
- the horizontal axis shows the protease inhibitor added to each pancreatin solution and its final concentration.
- sample solution 1 no inhibitor
- sample solution 2 AEBSF
- sample solution 3 AEBSF + PMSF
- sample solutions were reacted by incubation at 25 ° C. for 16 hours (room temperature storage). Thereafter, each sample solution was diluted 10-fold with the buffer attached to the CircuLex S100P ELISA Kit (manufactured by Cyclex, catalog number: CY-8060), and S100P was detected using the CircuLex S100P ELISA Kit. went. As a control, S100P was detected in the same manner for sample solution 1 immediately after preparation (that is, before storage at room temperature).
- the measurement results are shown in FIG.
- the vertical axis indicates the S100P concentration
- the horizontal axis indicates that the sample solution 1 was stored at room temperature (in the figure, “before room temperature”), and after the sample solutions 1 to 3 were stored at room temperature (in the figure, “no inhibitor”, “ AEBSF ”,“ AEBSF + PMSF ”).
- S100P was almost completely degraded in all pancreatic juice samples.
- sample solutions 2 and 3 to which a protease inhibitor was added S100P was detected in any pancreatic juice sample, and in particular, in sample solution 3 to which both AEBSF and PMSF were added, the S100P concentration was maintained high. From these results, it became clear that S100P in pancreatic juice is more stable at room temperature by mixing at least one, preferably two or more sulfone compounds having a sulfonyl fluoride group.
- Example 1 In order to detect S100P originally contained in human pancreatic juice specimens, not artificially added preparations, a sulfone compound having a sulfonyl fluoride group alone is insufficient. Therefore, with the aim of further improving the storage performance of S100P, it was investigated whether the storage stability of S100P is affected by the presence or absence of the combined use of a sulfone compound having a sulfonyl fluoride group and TLCK, which is another sulfone compound. Seven types of human clinical specimens were used.
- sample solution 1 AEBSF
- AEBSF final concentration: 4 mM
- PMSF final concentration: 1 mM
- sample solution (sample solution 2: AEBSF + PMSF), sample solution (sample solution 3) with AEBSF (final concentration: 4 mM), PMSF (final concentration: 1 mM) and aprotinin (final concentration: 3 ⁇ M) added to each human clinical specimen : AEBSF + PMSF + Aprotinin), sample solution in which AEBSF (final concentration: 4 mM), PMSF (final concentration: 1 mM) and TPCK (final concentration: 1 mM) are added to each human clinical sample (sample solution 4: AEBSF + PMSF + TPCK), AEBSF (final concentration: 4 mM) and PMSF (final concentration: 1 m) ) And TLCK (final concentration: 1 mM) added sample solution (sample solution 5: AEBSF + PMSF + TLCK) was prepared.
- sample solutions 1 to 5 were prepared from the same human clinical specimens as described above except that cryopreservation was performed instead of room temperature storage, and these sample solutions were prepared in the same manner as in Reference Example 2 with S100P. Was detected.
- the measurement results are shown in FIG.
- the vertical axis represents the S100P concentration
- the horizontal axis represents the sample solutions 1 to 5 for human pancreatic juice specimens 1 to 7 (in the figure, “AEBSF”, “AEBSF + PMSF”, “AEBSF + PMSF + Aprotinin”, “AEBSF + PMSF + TPCK”, “AEBSF + TLCK”) Show.
- “FT” indicates the result after freezing and without storage at room temperature
- “25 ° C., 16 h” indicates the result after incubation at 25 ° C. for 16 hours (after storage at room temperature). Show.
- sample solution 1 to which only AEBSF was added and sample solution 2 to which AEBSF and PMSF were added S100P was detected in all human pancreatic juice specimens, but the amount was much smaller than that in the case of cryopreservation. It was found that most S100P was decomposed and modified during storage at room temperature. In contrast, sample solution 5 to which AEBSF, PMSF, and TLCK were added showed an S100P concentration remaining rate of about 70% or more when cryopreserved in all human pancreatic juice specimens.
- sample solution 3 in which aprotinin was added to AEBSF and PMSF and sample solution 4 in which TPCK was added to AEBSF and PMSF a high residual rate was not found as in sample solution 5 in which AEBSF, PMSF, and TLCK were added.
- a protease inhibitor having at least one kind of sulfonyl fluoride group and an amino acid chloromethyl ketone having a trypsin-like serine protease inhibitory activity such as TLCK
- S100P in pancreatic juice can be obtained at room temperature. It was found that it can be stored very stably.
- sample solution 1 in which 25 ng / mL S100P (standard) solution was mixed with each of the two human clinical specimens (human pancreatic juice specimens 1 and 2) used in Example 1 and the simulated artificial pancreatic juice
- Sample solution 1 no inhibitor
- sample solution 1 added with AEBSF (final concentration: 4 mM)
- sample solution 2 AEBSF
- PMSF final concentration
- sample solution 3 AEBSF + PMSF
- sample solution 1 added with AEBSF final concentration: 4 mM
- PMSF final concentration: 1 mM
- TLCK final concentration: 1 mM
- Each sample solution was CircuLex S100P ELISA It was prepared using the buffer attached to Kit (manufactured by Cyclex, catalog number: CY-8060). After reacting these sample solutions by incubation at 25 ° C. for 16 hours (after storage at room temperature), S100P was detected in the same manner as in Reference Example 2. As a control, the sample solution 1 prepared in the same manner as described above was cryopreserved in place of room temperature storage, and immediately after that, S100P was detected in the same manner as in Reference Example 2.
- the measurement results are shown in FIG.
- the vertical axis indicates the S100P concentration
- the horizontal axis indicates the sample solutions 1 to 4 for the human pancreatic fluid samples 1 and 2 and the pseudo artificial pancreatic fluid containing S100P (in the figure, “no inhibitor”, “AEBSF”, “AEBSF + PMSF”, “AEBSF + PMSF + TLCK”).
- “FT” indicates the result after freezing and without storage at room temperature
- “25 ° C., 16 h” indicates the result after incubation at 25 ° C. for 16 hours (after storage at room temperature). Show.
- the added S100P was detected in both the human pancreatic juice specimen and the pancreatin solution.
- S100P by using a protease inhibitor having a sulfonyl fluoride group such as AEBSF and a trypsin-like serine protease inhibitor which is an amino acid chloromethyl ketone such as TLCK is used in combination.
- AEBSF a protease inhibitor having a sulfonyl fluoride group
- TLCK a trypsin-like serine protease inhibitor which is an amino acid chloromethyl ketone
- the preparation method of the present invention and the kit for room temperature storage of the present invention can stably store S100P, particularly proteins in biological samples such as pancreatic juice and duodenal juice, at room temperature, S100P in pancreatic juice It can be used in the field of analyzing cervical cancer, especially in the field of clinical examination for diagnosis and treatment of pancreatic cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(1) 膵液成分を含有する生体試料に、フッ化スルホニル基を有するプロテアーゼ阻害剤を少なくとも1種類、及びアミノ酸クロロメチルケトン類であるトリプシン様セリンプロテアーゼ阻害剤を少なくとも1種類を添加して膵液成分含有試料を調製する工程、を有する膵液成分含有試料の調製方法。
(2)前記膵液成分含有試料を調製する工程後、当該膵液成分含有試料を室温で保存する工程を更に有する、前記(1)に記載の膵液成分含有試料の調製方法。
(3) 前記フッ化スルホニル基を有するプロテアーゼ阻害剤が、PMSF、AEBSF、p-APMSF、4-(フルオロスルホニル)安息香酸、3-(フルオロスルホニル)安息香酸、2-アミノベンゼンスルホニルフルオリド、3-アミノベンゼンスルホニルフルオリド、4-アミノベンゼンスルホニルフルオリド、2-ニトロベンゼンスルホニルフルオリド、3-ニトロベンゼンスルホニルフルオリド、及び4-ニトロベンゼンスルホニルフルオリドからなる群より選択される、前記(1)の膵液成分含有試料の調製方法。
(4) 前記フッ化スルホニル基を有するプロテアーゼ阻害剤として、PMSF、AEBSF、及びp-APMSFからなる群より選択される2種以上の化合物を用いる、前記(1)又は(2)の膵液成分含有試料の調製方法。
(5) 前記トリプシン様セリンプロテアーゼ阻害剤が、TLCKである、前記(1)~(3)のいずれかの膵液成分含有試料の調製方法。
(6) 前記膵液成分含有試料の調製工程において、フッ化スルホニル基を有するプロテアーゼ阻害剤として、PMSF、AEBSF、又はp-APMSFをそれぞれ最終濃度1mM以上、4mM以上、2mM以上添加し、トリプシン様セリンプロテアーゼ阻害剤として、TLCKを最終濃度0.1mM以上添加する、前記(1)の膵液成分含有試料の調製方法。
(7) 前記生体試料が、膵液又は十二指腸液である、前記(1)~(5)のいずれか一の膵液成分含有試料の調製方法。
(8) フッ化スルホニル基を有するプロテアーゼ阻害剤を少なくとも1種類;アミノ酸クロロメチルケトン類であるトリプシン様セリンプロテアーゼ阻害剤を少なくとも1種類;を含む、膵液成分を含有する生体試料の室温保存用キット。
(9) 前記フッ化スルホニル基を有するプロテアーゼ阻害剤が、PMSF、AEBSF、及びp-APMSFからなる群より選択される1種以上の化合物である、前記(8)の室温保存用キット。
(10) 前記トリプシン様セリンプロテアーゼ阻害剤が、TLCKである、前記(8)又は(9)の室温保存用キット。
(11) 採取された体液を貯留するための貯留部を備える保存用容器を更に含み、前記貯留部に、前記フッ化スルホニル基を有するプロテアーゼ阻害剤及び前記トリプシン様セリンプロテアーゼ阻害剤が予め充填されている、前記(8)~(10)のいずれか一の室温保存用キット。
また、本発明の膵液成分を含有する生体試料の室温保存用キットを用いることにより、生体から採取された膵液や十二指腸液から、室温保存可能なS100P検査用の生体試料を、より簡便に調製することができる。
本発明の膵液成分含有試料の調製方法(以下、「本発明の調製方法」ということがある)は、膵液成分を含有する生体試料を、室温であっても、当該生体試料に含まれている成分のうち、特にS100Pの分解・変性を抑制して安定的に保存し得るように調製する方法である。すなわち、本発明の調製方法は、膵液成分を含有する生体試料に、フッ化スルホニル基を有するプロテアーゼ阻害剤を少なくとも1種類、及びアミノ酸クロロメチルケトン類であるトリプシン様セリンプロテアーゼ阻害剤を少なくとも1種類を添加して膵液成分含有試料を調製する工程を有するものであり、必要に応じて、S100Pの検出に供されるまで当該試料を室温で保存する工程を更に有することを特徴とする。
本発明の膵液成分を含有する生体試料の保存用キット(以下、「本発明の保存用キット」ということがある)は、フッ化スルホニル基を有するプロテアーゼ阻害剤を少なくとも1種類、及びアミノ酸クロロメチルケトン類であるトリプシン様セリンプロテアーゼ阻害剤を少なくとも1種類を有することを特徴とする。当該保存用キットに備えられているフッ化スルホニル基を有するプロテアーゼ阻害剤と特定のトリプシン様セリンプロテアーゼ阻害剤とを、膵液成分を含有する生体試料に添加することにより、S100Pの検出に供されるまでの間、室温で保存可能な膵液成分含有試料をより簡便に調製することができる。
膵液中の消化酵素の中で、その分解カスケードのトリガーとなっている酵素はセリンプロテアーゼであることが知られている。そこでまず、膵液中に含まれているプロテアーゼに対して阻害効果の高いセリンプロテアーゼ阻害剤のスクリーニングを行った。
具体的には、市販されているプロテアーゼ阻害剤の中から、セリンプロテアーゼをターゲットとし、膵液に対して阻害効果の高い阻害剤を探索した。用いたプロテアーゼ阻害剤は、アプロチニン(Roche社製)、ロイペプチン(Roche社製)、PMSF(Roche社製)、AEBSF(Roche社製)、p-APMSF(SIGMA社製)、メシル酸カモスタット(フォイパン;和光純薬社製)、メシル酸ガベキサート(FOY;和光純薬社製)、TLCK(SIGMA社製)、TPCK(SIGMA社製)である。なお、TPCKは、キモトリプシンに対する阻害活性を有するが、トリプシンに対する阻害活性を示さないアミノ酸クロロメチルケトン類である。
参考例1によって膵液中の消化酵素に対する阻害効果が高いことが明らかとなったスルホン系化合物に着目し、膵癌のマーカータンパク質として知られるS100P(カルシウム結合タンパク質)の膵液中における室温安定性に対する、各種スルホン系化合物の効果を調べた。すなわち、4種類のヒト臨床検体の膵液を用い、S100Pの標品タンパク質を添加した後、室温保存前後でS100P濃度が変化するかどうかを調べた。
具体的には、まず、25ng/mLのS100P(標品)溶液を各ヒト臨床検体に混合した試料溶液(試料溶液1:阻害剤なし)と、試料溶液1にAEBSF(最終濃度:4mM)を添加した試料溶液(試料溶液2:AEBSF)、試料溶液1にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)を添加した試料溶液(試料溶液3:AEBSF+PMSF)を調製した。各試料溶液は、CircuLex S100P ELISA Kit(Cyclex社製、カタログ番号:CY-8060)に付属のバッファーを用いて調製した。これらの試料溶液を25℃、16時間インキュベートすることにより反応させた(室温保存)。その後、各試料溶液をCircuLex S100P ELISA Kit(Cyclex社製、カタログ番号:CY-8060)に付属のバッファーを用いて10倍希釈した希釈液に対して、CircuLex S100P ELISA Kitを用い、S100Pの検出を行った。対照として、調製直後(すなわち、室温保存前)の試料溶液1についても、同様にして、S100Pの検出を行った。
人工的に添加された標品ではなく、ヒト膵液検体に元々含まれているS100Pを検出するためには、フッ化スルホニル基を有するスルホン系化合物のみでは不充分である。そのため、S100Pのさらなる保存性能の向上を目指し、フッ化スルホニル基を有するスルホン系化合物とその他スルホン系化合物であるTLCKの併用の有無により、S100Pの保存安定性が影響を受けるかを調べた。7種類のヒト臨床検体を用いた。
具体的には、各ヒト臨床検体にAEBSF(最終濃度:4mM)を添加した試料溶液(試料溶液1:AEBSF)、各ヒト臨床検体にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)を添加した試料溶液(試料溶液2:AEBSF+PMSF)、各ヒト臨床検体にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)とアプロチニン(最終濃度:3μM)を添加した試料溶液(試料溶液3:AEBSF+PMSF+Aprotinin)、各ヒト臨床検体にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)とTPCK(最終濃度:1mM)を添加した試料溶液(試料溶液4:AEBSF+PMSF+TPCK)、各ヒト臨床検体にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)とTLCK(最終濃度:1mM)を添加した試料溶液(試料溶液5:AEBSF+PMSF+TLCK)を調製した。各試料溶液は、CircuLex S100P ELISA Kit(Cyclex社製、カタログ番号:CY-8060)に付属のバッファーを用いて調製した。これらの試料溶液を25℃、16時間インキュベートすることにより反応させた後(室温保存後)、参考例2と同様にしてS100Pの検出を行った。
また、対照として、室温保存に代えて凍結保存を行った以外は、上記と同様にして同じヒト臨床検体から試料溶液1~5を調製し、これらの試料溶液について参考例2と同様にしてS100Pの検出を行った。
擬似人工膵液中におけるS100Pの保存安定性とヒト臨床検体中におけるS100Pの保存安定性とに対するプロテアーゼ阻害剤の効果を比較した。S100P含有擬似人工膵液としては、パンクレアチン溶液にS100P(標品)を25ng/mLとなるように添加した溶液を用いた。
具体的には、まず、25ng/mLのS100P(標品)溶液を、実施例1で用いたヒト臨床検体2種(ヒト膵液検体1及び2)と擬似人工膵液のそれぞれに混合した試料溶液(試料溶液1:阻害剤なし)と、試料溶液1にAEBSF(最終濃度:4mM)を添加した試料溶液(試料溶液2:AEBSF)、試料溶液1にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)を添加した試料溶液(試料溶液3:AEBSF+PMSF)、試料溶液1にAEBSF(最終濃度:4mM)とPMSF(最終濃度:1mM)とTLCK(最終濃度:1mM)を添加した試料溶液(試料溶液4:AEBSF+PMSF+TLCK)を調製した。各試料溶液は、CircuLex S100P ELISA
Kit(Cyclex社製、カタログ番号:CY-8060)に付属のバッファーを用いて調製した。これらの試料溶液を25℃、16時間インキュベートすることにより反応させた後(室温保存後)、参考例2と同様にしてS100Pの検出を行った。
また、対照として、前記と同様にして調製した試料溶液1について、室温保存に代えて凍結保存を行った後、直ちに参考例2と同様にしてS100Pの検出を行った。
Claims (11)
- 膵液成分を含有する生体試料に、フッ化スルホニル基を有するプロテアーゼ阻害剤を少なくとも1種類、及びアミノ酸クロロメチルケトン類であるトリプシン様セリンプロテアーゼ阻害剤を少なくとも1種類を添加して膵液成分含有試料を調製する工程;
を有する、膵液成分含有試料の調製方法。 - 前記膵液成分含有試料を調製する工程後、当該膵液成分含有試料を室温で保存する工程を更に有する、請求項1に記載の膵液成分含有試料の調製方法。
- 前記フッ化スルホニル基を有するプロテアーゼ阻害剤が、PMSF、AEBSF、p-APMSF、4-(フルオロスルホニル)安息香酸、3-(フルオロスルホニル)安息香酸、2-アミノベンゼンスルホニルフルオリド、3-アミノベンゼンスルホニルフルオリド、4-アミノベンゼンスルホニルフルオリド、2-ニトロベンゼンスルホニルフルオリド、3-ニトロベンゼンスルホニルフルオリド、及び4-ニトロベンゼンスルホニルフルオリドからなる群より選択される、請求項1に記載の膵液成分含有試料の調製方法。
- 前記フッ化スルホニル基を有するプロテアーゼ阻害剤として、PMSF、AEBSF、及びp-APMSFからなる群より選択される2種以上の化合物を用いる、請求項1に記載の膵液成分含有試料の調製方法。
- 前記トリプシン様セリンプロテアーゼ阻害剤が、TLCKである、請求項1に記載の膵液成分含有試料の調製方法。
- 前記膵液成分含有試料の調製工程において、フッ化スルホニル基を有するプロテアーゼ阻害剤として、PMSF、AEBSF、又はp-APMSFをそれぞれ、最終濃度1mM以上、4mM以上、2mM以上添加し、トリプシン様セリンプロテアーゼ阻害剤として、TLCKを最終濃度0.1mM以上添加する、請求項1に記載の膵液成分含有試料の調製方法。
- 前記生体試料が、膵液又は十二指腸液である、請求項1に記載の膵液成分含有試料の調製方法。
- フッ化スルホニル基を有するプロテアーゼ阻害剤を少なくとも1種類;
アミノ酸クロロメチルケトン類であるトリプシン様セリンプロテアーゼ阻害剤を少なくとも1種類;
を含む、膵液成分を含有する生体試料の室温保存用キット。 - 前記フッ化スルホニル基を有するプロテアーゼ阻害剤が、PMSF、AEBSF、及びp-APMSFからなる群より選択される1種以上の化合物である、請求項8に記載の室温保存用キット。
- 前記トリプシン様セリンプロテアーゼ阻害剤が、TLCKである、請求項9に記載の室温保存用キット。
- 採取された体液を貯留するための貯留部を備える保存用容器を更に含み、
前記貯留部に、前記フッ化スルホニル基を有するプロテアーゼ阻害剤及び前記トリプシン様セリンプロテアーゼ阻害剤が予め充填されている、請求項8に記載の室温保存用キット。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014520968A JP6210982B2 (ja) | 2012-06-22 | 2013-03-04 | 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット |
CN201380032761.9A CN104395749B (zh) | 2012-06-22 | 2013-03-04 | 含胰液成分的试样的调制方法、以及含胰液成分的生物试样的室温储存用试剂盒 |
EP13806851.5A EP2866029B1 (en) | 2012-06-22 | 2013-03-04 | Method for preparing sample containing pancreatic juice component, and kit for storing biological sample containing pancreatic juice component at room temperature |
US14/576,437 US9376675B2 (en) | 2012-06-22 | 2014-12-19 | Method for preserving components of pancreatic juice in a sample, and kit for preserving components of pancreatic juice in a sample |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012140796 | 2012-06-22 | ||
JP2012-140796 | 2012-06-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/576,437 Continuation US9376675B2 (en) | 2012-06-22 | 2014-12-19 | Method for preserving components of pancreatic juice in a sample, and kit for preserving components of pancreatic juice in a sample |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013190867A1 true WO2013190867A1 (ja) | 2013-12-27 |
Family
ID=49768476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/055828 WO2013190867A1 (ja) | 2012-06-22 | 2013-03-04 | 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット |
Country Status (5)
Country | Link |
---|---|
US (1) | US9376675B2 (ja) |
EP (1) | EP2866029B1 (ja) |
JP (1) | JP6210982B2 (ja) |
CN (1) | CN104395749B (ja) |
WO (1) | WO2013190867A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017073226A1 (ja) * | 2015-10-26 | 2017-05-04 | オリンパス株式会社 | 膵疾患の罹患可能性評価方法 |
CN107533044B (zh) * | 2015-11-11 | 2019-10-25 | 奥林巴斯株式会社 | 十二指肠液试样的保存方法 |
CN109563501A (zh) * | 2016-08-03 | 2019-04-02 | 株式会社岛津制作所 | 肽片段的制备方法和其中所使用的蛋白酶的制备方法、以及肽片段制备用试剂盒 |
US11446279B2 (en) * | 2017-06-29 | 2022-09-20 | The Regents Of The University Of California | Aromatic 2-nitrosulfonyl fluoride antibiotics and methods of use thereof |
CN117230155A (zh) * | 2023-09-19 | 2023-12-15 | 核工业总医院 | 一种十二指肠液样本的保存液及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085634B2 (ja) | 1987-04-30 | 1996-01-24 | 日産自動車株式会社 | フオ−クリフトのロ−ドプツシユ・プル制御装置 |
JP2003270237A (ja) | 2002-03-13 | 2003-09-25 | Toshiba Corp | 水質検出装置 |
JP2010025770A (ja) * | 2008-07-18 | 2010-02-04 | Noguchi Inst | α−アミラーゼアイソザイムの識別法 |
JP2011005009A (ja) | 2009-06-26 | 2011-01-13 | Olympus Corp | 標本採取チューブ及びそれを備える内視鏡装置 |
JP2011047802A (ja) * | 2009-08-27 | 2011-03-10 | Olympus Corp | 標的物質の濃度測定方法 |
WO2012137832A1 (ja) * | 2011-04-05 | 2012-10-11 | オリンパス株式会社 | 膵臓検査方法および膵臓検査キット |
WO2013038981A1 (ja) * | 2011-09-13 | 2013-03-21 | オリンパス株式会社 | 膵疾患マーカーの検出方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2484876C (en) | 2002-05-13 | 2011-11-22 | Becton, Dickinson And Company | Protease inhibitor sample collection system |
CN101084016A (zh) * | 2004-04-15 | 2007-12-05 | 克艾思马有限公司 | 能够容易穿透生物学障碍的组合物 |
CN101547702B (zh) | 2005-09-06 | 2016-06-22 | 奥拉姆德医药公司 | 用于口服给药蛋白质的方法和组合物 |
CN101340893B (zh) * | 2005-10-20 | 2012-03-21 | 玛瑞纳生物技术有限公司 | 速效胰岛素的鼻内施用 |
JP2007222062A (ja) | 2006-02-23 | 2007-09-06 | Ehime Univ | スーパーオキサイド発生剤およびその製造方法 |
US9482677B2 (en) | 2008-02-27 | 2016-11-01 | Scios Inc. | Method, composition and device for sampling natriuretic peptides in a biological fluid |
CN102307897B (zh) * | 2008-12-05 | 2016-01-20 | 葛兰素集团有限公司 | 选出蛋白酶抗性多肽的方法 |
JPWO2010134246A1 (ja) * | 2009-05-20 | 2012-11-08 | オリンパス株式会社 | 核酸含有試料の調製方法 |
JP2011250757A (ja) * | 2010-06-03 | 2011-12-15 | Olympus Corp | 生体試料中の核酸検出方法 |
JP6000956B2 (ja) * | 2011-09-13 | 2016-10-05 | オリンパス株式会社 | 膵液成分を含有する生体試料中のプロテアーゼの阻害方法 |
-
2013
- 2013-03-04 JP JP2014520968A patent/JP6210982B2/ja active Active
- 2013-03-04 WO PCT/JP2013/055828 patent/WO2013190867A1/ja active Application Filing
- 2013-03-04 CN CN201380032761.9A patent/CN104395749B/zh active Active
- 2013-03-04 EP EP13806851.5A patent/EP2866029B1/en active Active
-
2014
- 2014-12-19 US US14/576,437 patent/US9376675B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085634B2 (ja) | 1987-04-30 | 1996-01-24 | 日産自動車株式会社 | フオ−クリフトのロ−ドプツシユ・プル制御装置 |
JP2003270237A (ja) | 2002-03-13 | 2003-09-25 | Toshiba Corp | 水質検出装置 |
JP2010025770A (ja) * | 2008-07-18 | 2010-02-04 | Noguchi Inst | α−アミラーゼアイソザイムの識別法 |
JP2011005009A (ja) | 2009-06-26 | 2011-01-13 | Olympus Corp | 標本採取チューブ及びそれを備える内視鏡装置 |
JP2011047802A (ja) * | 2009-08-27 | 2011-03-10 | Olympus Corp | 標的物質の濃度測定方法 |
WO2012137832A1 (ja) * | 2011-04-05 | 2012-10-11 | オリンパス株式会社 | 膵臓検査方法および膵臓検査キット |
WO2013038981A1 (ja) * | 2011-09-13 | 2013-03-21 | オリンパス株式会社 | 膵疾患マーカーの検出方法 |
Non-Patent Citations (3)
Title |
---|
NAKATA, HUMAN PATHOLOGY, vol. 41, 2010, pages 824 - 831 |
OHUCHIDA, CLINICAL CANCER RESEARCH, vol. 12, no. 18, 2006, pages 5411 - 5416 |
See also references of EP2866029A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP6210982B2 (ja) | 2017-10-11 |
EP2866029A1 (en) | 2015-04-29 |
EP2866029A4 (en) | 2015-12-09 |
CN104395749B (zh) | 2016-12-28 |
US9376675B2 (en) | 2016-06-28 |
CN104395749A (zh) | 2015-03-04 |
EP2866029B1 (en) | 2017-05-03 |
US20150104846A1 (en) | 2015-04-16 |
JPWO2013190867A1 (ja) | 2016-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6000956B2 (ja) | 膵液成分を含有する生体試料中のプロテアーゼの阻害方法 | |
JP6210982B2 (ja) | 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット | |
Harwood et al. | Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis | |
AU2013322643B2 (en) | Stabilisation of biological samples | |
Peña et al. | Assessment of fresh and frozen–thawed boar semen using an Annexin-V assay: a new method of evaluating sperm membrane integrity | |
Šimaga et al. | Tumor cytosol dipeptidyl peptidase III activity is increased with histological aggressiveness of ovarian primary carcinomas | |
JP2010515012A (ja) | 組織保存および固定方法 | |
JPWO2010064634A1 (ja) | 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット | |
JP6382323B2 (ja) | 室温での全血の安定化 | |
JP2021164678A (ja) | 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管 | |
JP5201822B2 (ja) | ガストリン放出ペプチド前駆体の免疫学的測定方法 | |
US20190177774A1 (en) | Molecular reference controls | |
Liang et al. | Cryopreservation-altered expression of RNA and protein markers in biological specimens | |
Zhang et al. | Robust acquisition of spatial transcriptional programs in tissues with immunofluorescence-guided laser capture microdissection | |
JP2012230073A (ja) | 膵液成分保存用試料の調製方法 | |
JP6184654B1 (ja) | 十二指腸液試料の保存方法 | |
US20220003748A1 (en) | Method for preserving urinary cells | |
JP3781577B2 (ja) | Rnaの抽出及び長期保存方法 | |
Stawowy et al. | The molecular biology of furin-like proprotein convertases in vascular remodelling | |
Kepple et al. | Oxford Kidney Pathology Atlas: Single Cellular Profiling of Renal Biopsy Tissue: SA-PO847 | |
Guillen et al. | C5b-9 Deposition on Cultured Endothelial Cells in Patients with Thrombotic Microangiopathy of Different Etiology: SA-PO848 | |
EP4317454A1 (en) | Method for detecting microrna in biological sample, composition of hydrochloride of neutral amino acid, and container | |
Gujral et al. | HDAC class IIa expression and regulation in human endometrial tissues and stromal cells during the menstrual cycle | |
WO2024085786A1 (en) | Medium and device for collecting, storing and transporting | |
JP2023018634A (ja) | 生体試料中のマイクロrnaの検出方法、中性アミノ酸の塩酸塩の組成物および容器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13806851 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014520968 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013806851 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013806851 Country of ref document: EP |